After CAR-T Failure in Diffuse Large B-Cell Lymphoma, What Comes Next?
(MedPage Today) -- CD19-targeted chimeric antigen receptor (CAR) T-cells have emerged as a second- and later-line treatment strategy for patients with diffuse large B-cell lymphoma (DLBCL), with three FDA-approved products. "Across CAR T-cell...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.